Novartis plans to cut up to 130 Basel jobs as biologics work shifts to other sites and its campus.
Novartis is cutting up to 130 jobs in Basel
Keystone-SDA
The pharmaceutical company Novartis is cutting up to 130 jobs in Basel by the end of 2027. The reason, the company announced on Wednesday, is that it is discontinuing the small-scale production of biologics in the Kleinbasel district.
Generated with artificial intelligence.
This content was published on
Der Branchenriese will Hunderte Jobs in einem Werk nahe der deutschen Grenze streichen. Anderswo soll dagegen Personal aufgebaut…
Novartis is executing more layoffs at its U.S. headquarters in East Hanover, New Jersey, handing 322 employees pink slips. The…
Zimmer Biomet plans to cut 580 jobs at its Winterthur site as part of restructuring.
Two Big Pharmas are shrinking their U.S. | AbbVie's 85 layoffs are tied to its Allergan Aesthetics headquarters in California,…
The Australian pharmaceutical group CSL Behring has cut just under 10% of the workforce in Bern.
Manufacturing roundup: Novartis licenses Alteogen's Hybrozyme tech; Cellares cuts 68 more NJ jobs; Novonesis, Aspen, Fortrea and…
